Case study mitigating risk in biosimilar development

With an expected $67 billion worth of licenses on organic items lapsing before 2020 and governments forced to diminish quickly rising human services costs, biosimilars speak to a noteworthy open door for the pharmaceutical business. Biosimilars are exceptionally like their authorized reference item not withstanding minor contrasts as excipients in the plan; likewise there are no wonderful contrasts between the biologicals and the reference item as far as wellbeing, immaculateness, and strength. However, until a global development strategy is adopted, regulatory, therapeutic and legal challenges remain.

  • Impact of FDA Guidance on Substitution Policies
  • Chronicles of a Biosimilar Production Facility
  • challenges in developing monoclonal biosimilars

Related Conference of Case study mitigating risk in biosimilar development

June 06-07, 2018

International Conference & B2B on Pharma Research and Development

Philadelphia, Pennsylvania, USA
August 20-21, 2018

12th Asian Biologics and Biosimilars Congress

Tokyo, Japan
October 18-20, 2018

18th World Pharma Congress

Warsaw, Poland
November 15-16, 2018

14th International Conference on Generic Drugs and Biosimilars

Frankfurt, Germany
September 18-19, 2018

6 th European Biopharma Congress

Amsterdam, Netherlands

Case study mitigating risk in biosimilar development Conference Speakers

Recommended Sessions

Related Journals

Are you interested in